Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12857910 | 0.78 | MEN1 (0.72) | MEN1KMT2ARAB9ANPC1CYP1A2 | |
| SCHEMBL6526653 | 0.78 | HTT (0.54) | MEN1KMT2ACYP1A2LMNAGAA | |
| SCHEMBL1858111 | 0.76 | RAB9A (0.78) | MEN1KMT2ARAB9ANPC1TP53 | |
| SCHEMBL6448829 | 0.76 | LMNA (0.50) | MEN1KMT2ALMNAGAAMAPT | |
| SCHEMBL8358481 | 0.75 | ALOX15 (0.54) | MEN1KMT2ACYP1A2CYP2C19GAA | |
| SCHEMBL7189830 | 0.74 | ABCG2 (0.55) | MEN1KMT2AGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL27590288 | 0.74 | PTGS2 (0.50) | MEN1KMT2ACYP3A4L3MBTL1LMNA | |
| SCHEMBL6470479 | 0.73 | MEN1 (0.52) | MEN1KMT2ARAB9ANPC1CYP3A4 | |
| SCHEMBL6451275 | 0.73 | MEN1 (0.71) | MEN1KMT2ARAB9ANPC1TP53 | |
| SCHEMBL7175081 | 0.73 | RAB9A (0.53) | MEN1KMT2ARAB9ANPC1KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | MEN1 3473/4885KMT2A 3600/4885RAB9A 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.